Barclays (LON:BARC) analyst Julian Mitchell maintained a Hold rating on Colfax (NYSE:CFX) Corp on Thursday, setting a price target of $48, which is approximately 0.44% above the present share price of $47.79.
Mitchell expects Colfax Corp to post earnings per share (EPS) of $0.00 for the first quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Colfax, with an average price target of $47.7.
The analysts price targets range from a high of $53 to a low of $41.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $828.12 million and a net profit of $73.27 million. The company's market cap is $5.67 billion.
According to TipRanks.com, Barclays analyst Julian Mitchell is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.4% and a 70.81% success rate.
Colfax Corp. operates as a diversified technology company that provides orthopedic care and fabrication technology products and services to customers. The firm operates its business through the following segments: Medical Technology; and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices with a broad range of products used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures, and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Annapolis Junction, MD.